Lilly and QurCan Therapeutics have entered a multi-programme collaboration to develop nucleic-acid medicines for central and peripheral nervous system diseases using QurCan's TERP delivery platform. QurCan's polymer-lipid nanoparticle technology is designed to deliver genetic medicines beyond the liver and will be applied to selected CNS and PNS targets under the collaboration. QurCan is eligible for up to $237 million per programme in development and commercial milestones, as well as royalties, giving the agreement potentially substantial value across multiple programmes. Field Content Alert Type Deal Companies Eli Lilly and Company; QurCan Therapeutics Deal Type Strategic research and licensing collaboration Asset or Company TERP polymer-lipid nanoparticle delivery platform Therapy Area(s) Neurology; central nervous system; peripheral nervous system Technology or Modality Nucleic-acid therapeutics; polymer-lipid nanoparticles; genetic medicine Deal Value Up to US$237 million per programme in milestone payments, plus royalties Geography Global What Happened Lilly and QurCan Therapeutics entered a multi-programme collaboration to develop CNS and PNS genetic medicines using QurCan's TERP delivery technology. Why It Matters Efficient delivery remains a major challenge for genetic medicines outside the liver, and the collaboration gives Lilly access to a platform designed for broader tissue targeting. Supporting Context QurCan's TERP technology uses polymer-lipid nanoparticles designed to deliver nucleic-acid therapeutics to tissues including the central and peripheral nervous systems. Strategic Rationale Lilly gains access to a specialised delivery platform while QurCan receives development funding and potential milestone and royalty economics across multiple programmes. Potential Impact Successful programmes could expand the range of neurological diseases addressable with nucleic-acid medicines. Key Takeaway Lilly is partnering with QurCan on multiple genetic-medicine programmes, with potential payments of up to US$237 million per programme. What to Watch Selection of programme targets, preclinical development and evidence that TERP can achieve effective delivery in CNS and PNS tissues. Primary Source QurCan Therapeutics Relevant Date 15 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The FDA has expanded the approved use of Ameluz with red-light photodynamic therapy to include treatment of superficial basal cell carcinoma in adults. The approval makes Ameluz with Biofrontera's RhodoLED system the first FDA-approved photodynamic therapy for a skin cancer and provides a non-surgical treatment option for eligible patients. The expanded indication builds on Ameluz's established use in actinic keratosis and extends the company's photodynamic therapy platform into superficial basal cell carcinoma. Field Content Alert Type Approval Drug Name Aminolevulinic acid hydrochloride gel Brand Name Ameluz Company Biofrontera Regulatory Authority U.S. Food and Drug Administration Approval Type Label expansion Indication Treatment of superficial basal cell carcinoma in adults using Ameluz with red-light photodynamic therapy Therapy Area(s) Dermatology; oncology; skin cancer Technology or Modality Photodynamic therapy Device RhodoLED red-light system Geography United States What Happened The FDA approved an expanded indication for Ameluz with red-light photodynamic therapy to treat superficial basal cell carcinoma in adults. Why It Matters The approval establishes the first FDA-approved photodynamic therapy for a skin cancer and introduces a non-surgical option for eligible patients with superficial basal cell carcinoma. Supporting Context Ameluz is already used with red-light photodynamic therapy for actinic keratosis and is activated by the RhodoLED treatment system. Key Takeaway Ameluz with RhodoLED becomes the first FDA-approved photodynamic therapy for superficial basal cell carcinoma. What to Watch Dermatology adoption, reimbursement and uptake relative to surgical and other non-surgical treatment options. Primary Source Biofrontera Relevant Date 14 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The FDA has approved Curium's Bexlutry as the first radioligand equivalent to Lutathera for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours. Bexlutry, or lutetium Lu 177 dotatate, delivers targeted radiation to tumour cells expressing somatostatin receptors and provides a new radioligand treatment option for eligible patients with GEP-NETs. The approval introduces the first FDA-approved therapeutic equivalent to Novartis' Lutathera and could broaden access to radioligand therapy in neuroendocrine tumour care. Field Content Alert Type Approval Drug Name Lutetium Lu 177 dotatate Brand Name Bexlutry Company Curium Pharma Regulatory Authority U.S. Food and Drug Administration Approval Type New drug approval; radioligand therapeutic equivalent Indication Treatment of adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours Therapy Area(s) Oncology; neuroendocrine tumours Technology or Modality Radioligand therapy Reference Product Lutathera Geography United States What Happened The FDA approved Bexlutry (lutetium Lu 177 dotatate) for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours. Why It Matters Bexlutry is the first FDA-approved radioligand therapeutic equivalent to Lutathera, introducing another treatment option in an increasingly important precision-oncology modality. Supporting Context Lutetium Lu 177 dotatate targets somatostatin receptor-expressing tumour cells and delivers radioactive lutetium-177 directly to those cells. Key Takeaway Bexlutry becomes the first FDA-approved Lutathera equivalent for SSTR-positive GEP-NETs. What to Watch Commercial rollout, treatment-centre adoption and the effect of additional competition on access to radioligand therapy. Primary Source Curium Pharma Relevant Date 14 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The European Medicines Agency has opened consultation on a draft guideline addressing the design and interpretation of studies assessing drug absorption interactions within the gastrointestinal tract. The draft guidance focuses on situations where medicines may alter the absorption of other drugs through mechanisms including changes in gastric pH, gastrointestinal motility, binding or complex formation. Comments are open until 31 December 2026, after which EMA may revise the guideline before final adoption and implementation across European medicines development. Field Content Alert Type Industry Update Organisation European Medicines Agency Development Type Draft regulatory guideline and public consultation Topic Drug absorption interactions in the gastrointestinal tract Sector Pharmaceutical regulation; clinical pharmacology Geography European Union What Happened EMA opened a public consultation on a draft guideline covering the design, conduct and interpretation of studies assessing drug absorption interactions in the gastrointestinal tract. Why It Matters The guideline could influence how pharmaceutical companies design interaction studies and demonstrate the safety and effectiveness of medicines whose absorption may be altered by other drugs. Key Areas Gastric pH changes; gastrointestinal motility; binding and complex formation; study design; data interpretation Supporting Context Gastrointestinal interactions can affect drug exposure without involving conventional metabolic or transporter-mediated drug-drug interaction pathways. Potential Impact Final guidance could standardise European expectations for evaluating these interactions during medicine development and regulatory submissions. Key Takeaway EMA is developing more specific regulatory expectations for assessing drug absorption interactions occurring within the gastrointestinal tract. What to Watch Stakeholder feedback before the 31 December 2026 consultation deadline and subsequent publication of the final guideline. Primary Source European Medicines Agency Relevant Date 11 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

GSK has acquired full global rights to Chimagen Biosciences' trispecific T-cell engager programme for multiple myeloma in a transaction worth up to $750 million. The programme is designed to engage T cells against multiple myeloma through a trispecific antibody approach, adding another differentiated immuno-oncology asset to GSK's haematology pipeline. Chimagen is eligible for upfront and milestone payments worth up to $750 million, while GSK will assume responsibility for further global development and commercialisation of the programme. Field Content Alert Type Deal Companies GSK; Chimagen Biosciences Deal Type Global rights acquisition / licensing agreement Asset or Company Trispecific T-cell engager programme Therapy Area(s) Oncology; haematology; multiple myeloma Technology or Modality Trispecific T-cell engager Deal Value Up to US$750 million in upfront and milestone payments Geography Global What Happened GSK acquired full global rights to Chimagen Biosciences' trispecific T-cell engager programme for multiple myeloma. Why It Matters The deal adds a potentially differentiated next-generation immunotherapy to GSK's multiple myeloma pipeline and strengthens its position in haematologic oncology. Supporting Context The programme uses a trispecific antibody design intended to direct T cells against tumour targets associated with multiple myeloma. Strategic Rationale GSK gains control of an innovative early-stage oncology programme while Chimagen receives near- and long-term economics tied to development and commercial success. Potential Impact Successful development could provide a new treatment approach for patients with multiple myeloma and strengthen competition in the T-cell engager field. Key Takeaway GSK is committing up to US$750 million for global rights to Chimagen's trispecific T-cell engager programme in multiple myeloma. What to Watch Entry into clinical development, early safety and efficacy data and positioning against other T-cell engager and cell-therapy approaches in multiple myeloma. Primary Source GSK Relevant Date 15 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The FDA has approved shorter monitoring requirements following the first two doses of Amgen's Imdelltra, reducing observation time from 22–24 hours to 6–8 hours. The prescribing-information update applies to the initial step-up doses of Imdelltra and could make administration of the bispecific T-cell engager more practical in community oncology settings. The change may reduce the logistical burden associated with treatment while maintaining required monitoring for cytokine release syndrome and other early treatment-related risks. Field Content Alert Type Approval Drug Name Tarlatamab-dlle Brand Name Imdelltra Company Amgen Regulatory Authority U.S. Food and Drug Administration Approval Type Prescribing-information / monitoring requirement update Indication Extensive-stage small cell lung cancer under the existing approved indication Therapy Area(s) Oncology; lung cancer Technology or Modality Bispecific T-cell engager Monitoring Change Post-dose monitoring for the first two doses reduced from 22–24 hours to 6–8 hours Geography United States What Happened The FDA approved an update to Imdelltra's prescribing information reducing monitoring time after the first two doses from 22–24 hours to 6–8 hours. Why It Matters Shorter observation requirements could make Imdelltra easier to administer outside large specialist centres and reduce the logistical burden on patients and oncology providers. Supporting Context Imdelltra is a bispecific T-cell engager used in extensive-stage small cell lung cancer and requires monitoring for cytokine release syndrome during early dosing. Key Takeaway FDA-approved shorter monitoring requirements could broaden practical access to Imdelltra treatment. What to Watch Changes in community-oncology adoption, outpatient administration patterns and real-world safety following the reduced monitoring requirement. Primary Source Amgen Relevant Date 14 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Sanofi and Cheplapharm have agreed a major mature-medicines transaction covering 20 products and three manufacturing sites in France, Hungary and Singapore. Cheplapharm will take responsibility for the portfolio and manufacturing facilities, while Sanofi will receive a 26.4% equity stake in Cheplapharm as part of the strategic partnership. The transaction allows Sanofi to further concentrate resources on innovative medicines while transferring established products and manufacturing infrastructure to a company specialised in mature pharmaceutical brands. Field Content Alert Type Deal Companies Sanofi; Cheplapharm Deal Type Portfolio and manufacturing asset transfer; strategic partnership Asset or Company 20 mature medicines and three manufacturing sites Manufacturing Sites France; Hungary; Singapore Therapy Area(s) Multiple therapeutic areas Technology or Modality Mature pharmaceutical products and manufacturing operations Deal Value Sanofi to receive a 26.4% equity stake in Cheplapharm; additional financial terms not disclosed Geography Global What Happened Sanofi and Cheplapharm agreed to transfer 20 mature medicines and three manufacturing sites to Cheplapharm, with Sanofi receiving a 26.4% equity stake in the company. Why It Matters The transaction represents a substantial portfolio and manufacturing realignment and allows Sanofi to focus more resources on innovative medicines while maintaining economic participation through its Cheplapharm stake. Supporting Context Cheplapharm specialises in acquiring and managing established pharmaceutical brands and mature medicines. Strategic Rationale Sanofi is simplifying its portfolio and manufacturing footprint, while Cheplapharm gains a significant group of established products and production assets. Potential Impact The transaction could reshape supply and commercial management of the transferred medicines while strengthening Cheplapharm's manufacturing and product portfolio. Key Takeaway Sanofi is transferring 20 mature medicines and three manufacturing sites to Cheplapharm in exchange for a significant equity stake. What to Watch Regulatory approvals, completion of the transaction and integration of the medicines and manufacturing sites into Cheplapharm. Primary Source Sanofi Relevant Date 14 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Ori Biotech has entered a 10-year commercial partnership worth up to $120 million to integrate its IRO automated manufacturing platform into production of an autologous cell therapy. The agreement will deploy Ori's automated cell-therapy manufacturing technology across an undisclosed partner's commercial production process, supporting greater standardisation and manufacturing scalability. The long-term contract represents a significant commercial validation of Ori's platform as cell-therapy developers seek to reduce labour, variability and production complexity in advanced-therapy manufacturing. Field Content Alert Type Deal Companies Ori Biotech; undisclosed cell-therapy partner Deal Type Long-term commercial manufacturing technology partnership Asset or Company IRO automated cell-therapy manufacturing platform Therapy Area(s) Cell therapy; advanced therapies Technology or Modality Automated autologous cell-therapy manufacturing Deal Value Up to US$120 million over 10 years Geography Global What Happened Ori Biotech entered a 10-year agreement to integrate its IRO automated manufacturing platform into an undisclosed partner's commercial autologous cell-therapy manufacturing process. Why It Matters Commercial-scale manufacturing remains a major constraint in cell therapy, and the agreement provides significant validation of Ori's approach to automation and standardisation. Supporting Context Ori's IRO platform is designed to automate and digitally manage cell-therapy manufacturing processes with the aim of reducing labour requirements, variability and manufacturing cost. Strategic Rationale The partner gains access to an automated production platform, while Ori secures a long-term commercial deployment of its technology. Potential Impact Broader automation could improve consistency, scalability and economics for commercial cell-therapy production. Key Takeaway Ori Biotech has secured a 10-year cell-therapy manufacturing partnership worth up to US$120 million. What to Watch Commercial deployment of IRO, expansion to additional manufacturing sites and evidence of improved production efficiency. Primary Source Ori Biotech Relevant Date 15 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Hospital doctors working in Italy’s Servizio Sanitario Nazionale (SSN) received a new national collective agreement in 2026, bringing higher pay and updated allowances for medical and healthcare managers. The CCNL Area Sanità 2022–2024 was definitively signed on 27 February 2026 and applies to more than 137,000 healthcare managers, including around 120,000 doctors. ARAN says the agreement provides average increases of approximately €490 gross per month over 13 monthly payments, although the amount received by an individual doctor depends on role, responsibility and the components of their remuneration package. For hospital doctors in Italy, the important point is that there is not one single SSN salary figure. Pay is built from several elements, including: tabular salary; medical-specificity allowance; position allowance; responsibility payments; on-call and working-condition payments; performance-related remuneration; and additional allowances attached to particular roles. As a result, understanding what an Italian hospital doctor earns requires looking beyond the basic salary alone. What changed for hospital doctors in Italy in 2026? The new national contract introduced significant pay increases. According to ANAAO and CIMO-FESMED, the increases range from approximately: €322 gross per month for doctors in initial professional assignments to: €530 gross per month for directors of complex surgical structures. ARAN describes the average increase across the contract population as approximately: €490 gross per month for 13 monthly payments. These are increases generated by the new contract rather than complete physician salaries. A doctor’s total remuneration depends on the combination of contractual components applying to their role. What is the basic salary for an SSN medical manager? The new contract sets the gross annual tabular salary for medical managers at: €28,546.03 per year including the thirteenth-month payment. This number should not be interpreted as the full annual income of an SSN hospital doctor. It is only one component of the remuneration structure. Hospital doctors also receive other fixed and variable components, including medical-specificity and position allowances. That distinction is essential when comparing Italian physician pay with headline salaries in other countries. What is the medical-specificity allowance? The contract also provides an indennità di specificità medico-veterinaria. For medical and veterinary managers, the annual gross amount is: €9,466 per year including the thirteenth-month payment. This sits alongside the tabular salary rather than replacing it. So even before considering position-related pay, responsibility allowances, on-call activity or performance components, an Italian hospital doctor’s remuneration already consists of multiple separate elements. How does position affect a hospital doctor’s pay? One of the most important components is the retribuzione di posizione — position-related remuneration. The amount depends on the type and level of responsibility assigned to the doctor. The new contract sets the fixed annual gross position component at: Role Fixed annual position remuneration Initial professional assignment €2,511 Professional / consultancy / research assignment €6,798 High-specialisation professional assignment €8,034 Simple structure within a complex structure €13,143 Departmental/district simple-structure director €14,935 Complex structure director – medical area €20,312 Complex structure director – surgical area €21,506 These figures are annual gross amounts paid over 13 months. The full position payment can also contain a variable component. The contract sets much higher maximum overall position values depending on the post. For example: an initial professional assignment can reach €30,891 in total position remuneration; a high-specialisation professional assignment can reach €43,339; a departmental high-professionalism role can reach €44,060; a complex-structure directorship can reach €52,966. This is why a single headline “doctor salary in Italy” can be misleading. Responsibility and appointment type materially affect compensation. How much more do senior doctors receive? The new contract strengthens remuneration for doctors who take on greater clinical and managerial responsibility. For directors of complex structures, there is also a separate annual allowance. From the contractual effective date, the indennità di direzione di struttura complessa is: €11,157 gross per year paid over 13 months. For senior doctors running major hospital units, this sits on top of the other applicable remuneration components. A director of a complex surgical structure may therefore receive: tabular salary; medical-specificity allowance; position remuneration; complex-structure director allowance; performance-related pay; working-condition payments; and other applicable supplements. This helps explain why senior hospital-doctor compensation can be substantially higher than the basic tabular salary suggests. Does seniority affect position pay? Yes. For doctors with an exclusive employment relationship and a positive assessment, the contract guarantees minimum total position remuneration according to seniority. The minimum annual gross amounts are: €6,798 for at least 5 but under 15 years of service; €7,600 for at least 15 but under 20 years; €9,100 for 20 years or more. Seniority therefore affects compensation even where a physician does not move into a formal management post. Is the contractual increase the same for every hospital doctor? No. The 2026 agreement does not simply add one uniform amount to every physician’s salary. ANAAO and CIMO-FESMED report increases ranging from: €322 gross per month for initial professional appointments to: €530 gross per month for directors of complex surgical structures. The difference reflects the fact that the contract increased several remuneration components, including: basic salary; fixed position pay; medical-specificity allowances; and complex-structure leadership allowances. ARAN also states that the fixed position element for newly appointed managers increased substantially, with the change intended to improve the attractiveness of entry into the SSN. Are on-call shifts included? Not fully. Italian hospital-doctor pay can also include additional remuneration associated with working conditions and duties such as: guardia; pronta disponibilità; additional working time; emergency-department activity; nights; holidays; and other specific organisational responsibilities. These amounts are important because they can increase total annual remuneration beyond the fixed contractual components. For physicians working frequent nights or emergency duties, the difference between basic remuneration and actual gross earnings can therefore be significant. Does specialty affect the national SSN salary? Not directly in the same way as a specialty-specific compensation survey. The national contract is primarily structured around: employment status; assignment type; professional responsibility; managerial responsibility; seniority; and working conditions. A cardiologist, oncologist or neurologist holding a comparable SSN appointment is therefore operating within the same underlying national contractual framework. There is, however, one notable distinction in the contract. For directors of complex structures, the fixed position allowance differs between the surgical area and the medical area: Surgical complex-structure director: €21,506 per year Medical complex-structure director: €20,312 per year That is a role-based contractual distinction rather than evidence that one medical specialty generally earns more than another. Can we calculate one annual salary for an Italian hospital doctor? Not accurately from the national contract alone. For example, it would be misleading simply to quote the €28,546.03 tabular salary as an Italian hospital doctor's annual salary. That figure excludes major contractual components. At minimum, total fixed remuneration can involve: €28,546.03 tabular salary; €9,466 medical-specificity allowance; position-related remuneration; and potentially other role-specific fixed allowances. Variable and additional payments can then sit on top. The correct interpretation is therefore that the CCNL provides a remuneration framework, rather than one universal physician salary. Why is the 2026 contract important? The agreement is particularly significant because it is newly effective in 2026 and directly applies to Italy’s public health-service workforce. It covers approximately: 120,000 doctors and: 17,000 non-medical healthcare managers. The new contract increases both entry-level and senior-role remuneration and changes several of the components that make up physician pay. For hospital doctors, this makes the 2026 agreement a much stronger current benchmark than older national earnings averages. What should hospital doctors in Italy take from the 2026 data? The central message is that there is no single SSN hospital-doctor salary. The new contract establishes a basic annual tabular salary of: €28,546.03 plus a medical-specificity allowance of: €9,466 with position remuneration ranging from: €2,511 for an initial professional assignment to: €21,506 in fixed position pay for a director of a complex surgical structure before variable position pay and other allowances are considered. The 2026 contractual increases themselves range from approximately: €322 to €530 gross per month depending on the doctor's appointment. For an individual hospital doctor, the most useful question is therefore not simply: “What is the salary of a doctor in Italy?” It is: “Which SSN contractual components apply to my role, and how much do my position, seniority, responsibilities and additional duties add to my fixed pay?” That provides a much more meaningful way to understand hospital-doctor compensation in Italy. Source: ARAN, Contratto Collettivo Nazionale di Lavoro dell’Area Sanità – Triennio 2022–2024, definitively signed 27 February 2026. Additional context on the contractual increases from ANAAO Assomed and CIMO-FESMED. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Hospital doctors employed in France under the Praticien Hospitalier (PH) status have a published gross annual salary scale ranging from €55,607.79 to €112,416.56, depending on seniority and salary step. The current PH remuneration framework uses 13 salary steps, or échelons, with pay increasing as a physician progresses through the public hospital career structure. The official scale is set out in the national remuneration order for medical staff working in public health establishments. For physicians comparing hospital compensation in France, the most important point is that these figures represent gross hospital emoluments before additional allowances and payments. They are therefore a base remuneration benchmark rather than a complete measure of total annual earnings. What is the salary for a Praticien Hospitalier in France? The official PH salary scale runs from: €55,607.79 gross per year at échelon 1 to: €112,416.56 gross per year at échelon 13. The full published scale is: PH salary step Gross annual hospital emoluments Échelon 1 €55,607.79 Échelon 2 €58,082.41 Échelon 3 €62,148.07 Échelon 4 €66,567.09 Échelon 5 €68,688.21 Échelon 6 €71,162.83 Échelon 7 €76,465.74 Échelon 8 €79,647.54 Échelon 9 €90,549.14 Échelon 10 €94,557.64 Échelon 11 €99,810.26 Échelon 12 €105,062.89 Échelon 13 €112,416.56 These amounts are the official annual gross hospital emoluments for PHs. What does this mean in monthly terms? On a simple annual ÷12 basis, the scale equates approximately to: €4,634 per month at échelon 1 €9,368 per month at échelon 13 These monthly figures are useful for comparison, but the official French source publishes the PH scale as annual gross remuneration, not as a monthly salary table. How much does experience affect PH pay? A great deal. Progression from the first to the final PH step increases published annual gross hospital remuneration from: €55,607.79 to: €112,416.56 That is a difference of more than €56,800 per year across the career scale. For hospital doctors in France, seniority and progression through the échelons are therefore central to understanding base remuneration. The relevant question is not simply: “What does a hospital doctor earn in France?” It is also: “Which PH échelon applies to my current career stage?” Is this the total amount a Praticien Hospitalier earns? Not necessarily. The published PH scale represents hospital emoluments, but public-hospital doctors can also qualify for additional payments depending on their role and working arrangements. One of the most important is the: Indemnité d'engagement de service public exclusif The official remuneration order sets this allowance at: €1,010 per month for eligible physicians who commit to exclusive public service. On a 12-month basis, that could add: €12,120 gross per year to a physician's remuneration where the conditions are met. This means that a PH on the standard salary scale may receive significantly more than the base hospital emoluments alone. What is the prime d'exercice territorial? The official remuneration framework also provides a prime d'exercice territorial for eligible doctors working across sites. The monthly gross amounts are: €250 for one half-day per week outside the principal site €450 for more than one and up to three half-days €700 for more than three and up to four half-days €1,000 for four half-days across at least two additional sites, or more than four half-days These payments sit on top of the core PH remuneration where the relevant conditions are met. Are on-call and night duties included in the PH salary scale? No. The core salary scale should not be treated as a measure of all compensation associated with hospital work. Hospital physicians may receive additional remuneration for activities such as: permanence des soins; nights; weekends; public holidays; additional working time; and specific organisational responsibilities. These components can materially increase annual gross income beyond the published PH scale. For compensation comparisons, that distinction is crucial. A French PH base salary should not be directly compared with another country's physician-income survey if that survey includes overtime, on-call work, private activity or other additional earnings. Does specialty affect the PH salary scale? The PH scale itself is not specialty-specific. A cardiologist, neurologist, oncologist, radiologist or other specialist working under PH status is paid according to the relevant PH career scale rather than a separate nationally published salary table for each specialty. The data should therefore be interpreted as a benchmark for: public-hospital specialist physicians employed as Praticiens Hospitaliers rather than as evidence of what an individual specialty earns. That distinction matters for specialty-led compensation analysis. If we want to answer: “What do cardiologists earn in France?” we need cardiology-specific evidence. The PH scale instead answers: “What is the base public-hospital remuneration structure for specialist doctors employed under PH status in France?” How does this differ from private-practice physician income? It is a completely different type of compensation evidence. The PH scale applies to physicians employed within the public hospital system. Private-practice doctors may derive income from: consultations; procedures; reimbursement tariffs; private billing arrangements; and practice activity. Those figures should not be mixed with the PH salary scale. For example, Ameli consultation tariffs are reimbursement amounts per consultation or act, whereas the PH scale is employment remuneration. Likewise, CARMF income data reflects independent-practice professional income rather than public-hospital salary. Each dataset answers a different question. What should hospital doctors in France take from the 2026 salary data? For Praticiens Hospitaliers, the current official remuneration framework provides a clear base-pay benchmark. Gross annual hospital emoluments range from: €55,607.79 at échelon 1 to: €112,416.56 at échelon 13. Eligible physicians may then receive additional compensation such as: €1,010 per month for the exclusive public-service commitment allowance and up to: €1,000 per month in territorial-practice allowance depending on eligibility and working arrangements. The most useful question for an individual hospital doctor is therefore not simply: “What is the salary of a hospital doctor in France?” It is: “Which PH échelon applies to me, and which allowances and additional payments sit on top of my base hospital remuneration?” That provides a much more accurate picture of physician compensation within the French public hospital system. Source: Official French public-hospital medical remuneration scale under the Arrêté du 29 juin 2023 modifying the Arrêté du 8 juillet 2022, Annex II — Praticiens Hospitaliers. The official scale remains published by Légifrance. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Specialist doctors working in Spain’s public health system can see a substantial difference in their gross monthly pay depending on the autonomous community in which they work. The latest 2026 remuneration data for Facultativos Especialistas de Área (FEA) — hospital specialist physicians — shows ordinary gross monthly compensation ranging from approximately €3,066 to €4,813, before seniority payments and on-call duties are added. That creates a difference of more than €1,700 per month between regional health services. For hospital specialists in Spain, this is an important point: while parts of the public-sector salary structure are nationally standardised, regional supplements mean that the amount appearing on a specialist physician's payslip can vary considerably depending on where they work. What does a specialist doctor earn in Spain in 2026? According to the 2026 regional salary analysis, the ordinary gross monthly remuneration for an FEA without seniority payments or on-call duties is: Autonomous community Health service Gross monthly FEA pay Basque Country Osakidetza €4,813 Valencian Community Sanitat €4,206 Balearic Islands IB-Salut €4,202 La Rioja SERIS €4,135 Aragón SALUD €4,083 Madrid SERMAS €4,027 Ceuta & Melilla INGESA €4,008 Andalucía SAS €4,000 Canary Islands SCS €3,973 Cantabria SCS €3,789 Catalonia ICS €3,648 Asturias SESPA €3,624 Navarra SNS-O €3,501 Galicia SERGAS €3,345 Castilla y León SACYL €3,172 Castilla-La Mancha SESCAM €3,128 Murcia SMS €3,066 These figures refer to an ordinary month's gross remuneration, without trienios for seniority and without guardias. They should therefore be treated as a benchmark for fixed monthly public-sector compensation rather than a measure of a specialist's complete annual earnings. Why does specialist doctor pay vary so much across Spain? Spain's public-sector physician salary is made up of several components. For an FEA, the common elements include: Base A1 salary: €1,387.24 per month Destination supplement: €729.14 per month for level 24 Seniority payment: €53.39 per month for each three-year period of service Specific and productivity supplements: approximately €950 to €3,400 per month depending on the regional health service On-call payments: paid separately and set regionally The nationally determined base components therefore tell only part of the compensation story. The major differences arise from the complemento específico, productivity payments and other remuneration determined by each autonomous community. For a specialist doctor considering compensation in Spain, location can consequently make a meaningful difference even when the underlying clinical grade is similar. What does an FEA mean in Spain? FEA stands for Facultativo Especialista de Área. In practical terms, it refers to a specialist physician working within the hospital-based public health system. The category can include doctors working across specialties such as: cardiology; oncology; neurology; radiology; gastroenterology; pulmonology; dermatology; and other hospital specialties. However, the 2026 remuneration data does not provide separate salary scales for these individual specialties. It should therefore not be interpreted as showing a specific salary for a cardiologist, oncologist or neurologist. The figures provide a compensation benchmark for the FEA employment category. For an individual specialist, clinical specialty may influence workload, working patterns and opportunities for additional remuneration, but the regional salary figures themselves are not specialty-specific. How much does a specialist doctor earn in the Basque Country? The 2026 data shows an ordinary gross monthly FEA remuneration figure of approximately: €4,813 per month for the Basque Country. Official 2026 Osakidetza remuneration documentation separately confirms that the annual remuneration framework for a standard Facultativo position is €45,875.43, before considering every possible additional payment or individual circumstance. This illustrates an important methodological point: monthly salary comparisons and annual public-sector remuneration tables do not always describe exactly the same components. Physicians should therefore examine the individual elements included in any figure before making direct comparisons. How much does an FEA earn in Madrid? For Madrid, the ordinary gross monthly FEA figure in the regional comparison is approximately: €4,027 per month before seniority and guardias. But that figure does not tell the whole compensation story. On-call work can add substantially to a hospital specialist's earnings. From August 2026, the Community of Madrid increased physician guardia payments to: €484.31 for a standard working-day guardia €748.57 for a guardia performed on a public holiday with further increases scheduled for 2027. This demonstrates why two specialists with the same underlying FEA salary can ultimately receive very different total annual compensation depending on their working patterns. How important are guardias to specialist physician earnings? Very important. On-call work — guardias — is generally paid in addition to the ordinary monthly remuneration. The 2026 analysis estimates that guardias can contribute approximately: €12,000 to €24,000 in additional gross income per year depending on the number performed and the rates applied by the relevant autonomous community. This means that an FEA's headline monthly salary should not automatically be interpreted as their total earning potential. A specialist undertaking frequent nights, weekends and public-holiday guardias may have substantially higher gross annual earnings than another specialist on the same fixed remuneration but with fewer additional duties. What other payments can increase a specialist doctor's income? Beyond ordinary salary and guardias, several other components can affect remuneration. Seniority — trienios Doctors receive an additional payment for completed periods of service. The 2026 national A1 figure cited for a three-year period is approximately: €53.39 per month for each trienio. A physician with a longer public-sector career may therefore receive more than a newly appointed specialist. Professional career progression Many regional health systems also operate carrera profesional systems recognising experience, training and professional development. The amounts differ by autonomous community and career level. According to the 2026 analysis, these supplements can range from roughly €130 per month at lower stages to considerably higher amounts at advanced career levels in some regions. Exclusivity or dedication supplements Some health services also offer remuneration connected with exclusive dedication to the public system or incompatibility with private practice. Again, these arrangements differ significantly between regions. Is €3,066–€4,813 the total monthly income of a specialist doctor? Not necessarily. The clearest interpretation of these figures is: They represent ordinary gross monthly FEA remuneration before seniority and guardia payments. A specialist's actual compensation may include: base salary; destination supplement; specific supplement; productivity payments; seniority; professional career payments; guardias; nights and public-holiday payments; and other regional supplements. This distinction is essential when comparing physician salaries. A €4,000 ordinary monthly figure should not be compared directly with another dataset reporting total annual earnings including extensive on-call work. Why is the region so important for specialist doctors in Spain? Spain operates a decentralised health system. Although some salary components are nationally defined, autonomous communities administer their own health services and determine important additional remuneration. The result is that two hospital specialists employed within the Spanish public health system can have materially different fixed compensation depending on where they work. According to the 2026 figures, the difference between the highest and lowest ordinary FEA monthly remuneration is approximately: €1,747 per month. For specialists evaluating a role, salary comparisons should therefore consider the regional health service rather than relying on a single "Spanish doctor salary". Does this tell us what cardiologists or oncologists earn? Not specifically. This dataset is useful because it provides a current benchmark for hospital specialist physicians as an employment group. It does not provide separate compensation figures for cardiology, oncology, radiology, neurology or other individual specialties. A cardiologist working as an FEA should therefore use the relevant regional FEA figure as a public-sector employment benchmark — not as evidence of a cardiology-specific national salary. The same applies to other hospital specialties. Specialty-specific compensation analysis requires specialty-specific evidence. What should specialist doctors in Spain take from the 2026 data? For hospital specialists working in Spain's public health system, the most important finding is that there is no single FEA salary that accurately describes compensation throughout the country. Ordinary gross monthly FEA remuneration in the latest 2026 data ranges from approximately: €3,066 to €4,813 per month before seniority and guardias are included. Additional duties can then have a major effect on total remuneration, particularly guardias. For an individual specialist physician, the more useful question is therefore not simply: “How much does a specialist doctor earn in Spain?” It is: “What is the fixed FEA remuneration in my autonomous community, and how much do seniority, career progression and guardias add to my total compensation?” That provides a much more meaningful benchmark for understanding specialist physician pay in Spain. Sources: 2026 regional physician remuneration tables compiled by CalculadorNomina.es from national and autonomous-community salary documentation, including SERMAS, ICS, SAS, Osakidetza, SERGAS and other regional health services. The comparison was published on 23 July 2026. Official 2026 remuneration documentation from Osakidetza and the Community of Madrid was also reviewed as supporting evidence. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Cardiff Oncology and Nerviano have resolved their licensing dispute and amended the global onvansertib licence agreement, updating exclusivity, economics and termination provisions. The companies have settled litigation relating to Cardiff's rights to onvansertib and revised the terms of their 2017 exclusive worldwide licence agreement without either party making a settlement payment. The amended agreement provides a clearer commercial framework for continued development of onvansertib, Cardiff's PLK1 inhibitor being evaluated across multiple oncology indications. Field Content Alert Type Deal Companies Cardiff Oncology; Nerviano Medical Sciences Deal Type Licence amendment and dispute settlement Asset or Company Onvansertib Therapy Area(s) Oncology Technology or Modality PLK1 inhibitor; small-molecule targeted therapy Deal Value No settlement payment; revised licence economics and contractual terms Geography Worldwide What Happened Cardiff Oncology and Nerviano resolved litigation over the global rights to onvansertib and amended their 2017 exclusive worldwide licence agreement. Why It Matters The settlement removes legal uncertainty around Cardiff's principal oncology asset and establishes updated commercial and contractual terms for its continued development. Supporting Context Onvansertib is an oral small-molecule inhibitor of polo-like kinase 1, or PLK1, being developed by Cardiff Oncology in multiple cancer settings. Strategic Rationale The revised agreement gives both companies greater clarity around exclusivity, economics and termination rights while allowing Cardiff to continue advancing onvansertib. Potential Impact Resolution of the dispute reduces a potential development and financing overhang for Cardiff's oncology pipeline. Key Takeaway Cardiff Oncology and Nerviano have settled their onvansertib licensing dispute and agreed revised terms governing the global programme. What to Watch Further clinical development of onvansertib and the practical impact of the revised licence economics on Cardiff's commercial strategy. Primary Source Cardiff Oncology Relevant Date 11 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com